Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Aplastic Anemia: Demographic and Clinical Characteristics in Costa Rica.
Cureus
November 2024
Research Unit, Hospital San Juan de Dios, Costa Rican Social Security Health Fund (CCSS), San José, CRI.
Background Aplastic anemia (AA) is a rare and heterogeneous hematological disorder defined as pancytopenia with hypocellular bone marrow in the absence of abnormal infiltration or medullary fibrosis. Various causes of AA have been identified, such as autoimmune factors, bone marrow injuries, viral infections, and genetic disorders. The symptoms of AA are directly linked to pancytopenia and the most common are fatigue, recurrent infections, and bleeding problems.
View Article and Find Full Text PDFCyclosporin for the treatment of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): a systematic review of observational studies and clinical trials focusing on single therapy, combination therapy, and comparative assessments.
Inflammopharmacology
October 2024
Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences (IUMS), Rasool Akram Hospital, Niayesh Street, Sattar Khan Avenue, Tehran, 1445613131, Iran.
Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, severe, and potentially life-threatening skin and mucous membrane disorders. They are characterized by widespread skin and mucosal detachment and necrosis, and are classified based on the percentage of total body surface area (TBSA) affected. Given the severe and often life-threatening nature of these conditions, the identification and implementation of effective treatments is crucial.
View Article and Find Full Text PDFPPP3CB overexpression mediates EGFR TKI resistance in lung tumors via calcineurin/MEK/ERK signaling.
Life Sci Alliance
December 2024
University Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team RNA Splicing, Cell Signaling and Response to Therapy, Institute for Advanced Biosciences, Grenoble, France
Despite initial high response rates to first-line EGFR TKI, all non-small-cell lung cancer (NSCLC) with EGFR-activating mutation will ultimately develop resistance to treatment. Identification of resistance mechanisms is critical to adapt treatment and improve patient outcomes. Here, we show that a transcript that encodes full-length catalytic subunit 2B of calcineurin accumulates in EGFR-mutant NSCLC cells with acquired resistance against different EGFR TKIs and in post-progression biopsies of NSCLC patients treated with EGFR TKIs.
View Article and Find Full Text PDFThe relationship between Sjögren's syndrome and recurrent pregnancy loss: a bioinformatics analysis.
Reprod Biomed Online
December 2024
Department of Reproductive Medicine, Lanzhou University Second Hospital, Lanzhou, China. Electronic address:
Article Synopsis
- The study investigates the gene relationships between Sjögren's syndrome, an autoimmune disease, and recurrent pregnancy loss (RPL), suggesting a possible connection between their biological pathways.
- Researchers used gene datasets and advanced analyses (WGCNA and limma) to identify co-expressed genes, leading to the discovery of a shared hub gene, KCNN3, which is up-regulated in both conditions.
- The findings indicate that KCNN3 has links to immune responses and drug sensitivity, and may serve as a potential target for further research on Sjögren's syndrome and RPL.
Cyclosporin A as an Add-On Therapy to a Corticosteroid-Based Background Treatment in Patients with COVID-19: A Multicenter, Randomized Clinical Trial.
J Clin Med
September 2024
Fundación Jiménez Díaz (FJD) University Hospital, FJD Health Research Institute, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain.
: In susceptible hosts, SARS-CoV2-induced hyperinflammation accounts for an increased mortality. The search of adjuvant immunomodulatory therapies has been ongoing ever since the pandemic outbreak. Aim: Our purpose was to evaluate the efficacy of cyclosporin A (CsA) as an add-on therapy to the standard of care (SoC) in patients with severe COVID-19 pneumonia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!